Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NRXS

Neuraxis Inc

Dec 08 • 04:00PM ET

2.80

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.61	Insider Own	46.82%	Shs Outstand	6.14M	Perf Week	-14.37%
Market Cap	14.42M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.74M	Perf Month	15.23%
Income	-9.90M	PEG	-	EPS next Q	-	Inst Own	1.06%	Short Float / Ratio	0.80% / 0.56	Perf Quarter	-46.15%
Sales	2.54M	P/S	5.68	EPS this Y	-	Inst Trans	-	Short Interest	0.02M	Perf Half Y	-
Book/sh	-0.21	P/B	-	EPS next Y	-	ROA	-	Target Price	7.50	Perf Year	-
Cash/sh	0.15	P/C	18.97	EPS next 5Y	-	ROE	-	52W Range	1.80 - 6.93	Perf YTD	-53.33%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-59.60%	Beta	-
Dividend %	-	Quick Ratio	0.41	Sales past 5Y	19.82%	Gross Margin	87.95%	52W Low	55.56%	ATR	0.38
Employees	-	Current Ratio	0.43	Sales Q/Q	-30.05%	Oper. Margin	-236.95%	RSI (14)	49.38	Volatility	10.98% 13.48%
Optionable	No	Debt/Eq	-	EPS Q/Q	-9.52%	Profit Margin	-389.47%	Rel Volume	0.14	Prev Close	2.80
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 20 AMC	Payout	-	Avg Volume	38.83K	Price	2.80
Recom	1.00	SMA20	1.59%	SMA50	-1.81%	SMA200	-21.97%	Volume	5,360	Change	0.00%

Nov-20-23 05:30PM	NeurAxis Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-15-23 09:00AM	NeurAxis Announces CareFirst BCBS Policy Coverage (GlobeNewswire) +14.17%
Nov-14-23 09:00AM	NeurAxis Secures $3 Million Financing (GlobeNewswire)
Nov-08-23 09:00AM	NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device (GlobeNewswire)
Sep-26-23 09:00AM	NeurAxis Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders (GlobeNewswire)
08:00AM	Loading…
Sep-21-23 08:00AM	NeurAxis Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Sep-13-23 09:00AM	NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire) +7.87%
Sep-12-23 10:15AM	EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome (Benzinga) -16.92%
09:00AM	NeurAxis Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS (GlobeNewswire)
Aug-29-23 09:00AM	NeurAxis Highlights Pediatric Post-Concussion Clinical Study (GlobeNewswire)
Aug-24-23 09:00AM	NeurAxis Highlights Strength of its Board of Directors (GlobeNewswire) -10.15%
Aug-22-23 09:00AM	NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome (GlobeNewswire) +16.50%
Aug-17-23 09:02AM	NeurAxis Announces Over $8 Million in IB-Stim Revenue (GlobeNewswire)
Aug-15-23 09:00AM	NeurAxis Announces Positive University of Michigan IB-Stim Cost Effectiveness Study at ANMS 2023 (GlobeNewswire)
Aug-11-23 09:30AM	Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc. (ACCESSWIRE)
09:00AM	Loading…
Aug-10-23 09:00AM	NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin (GlobeNewswire)
09:00AM	Exchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE Listing (GlobeNewswire)
Aug-09-23 10:00AM	NeurAxis Announces Pricing of Initial Public Offering (GlobeNewswire)

NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. Its product IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXS

Neuraxis Inc

Upgrade your FINVIZ experience